We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Biomarker Identified for Two Different Cancers

By LabMedica International staff writers
Posted on 17 Apr 2014
Image: Histopathology of laryngeal squamous cell carcinoma (Photo courtesy of Masaryk University).
Image: Histopathology of laryngeal squamous cell carcinoma (Photo courtesy of Masaryk University).
A new biomarker linked to better outcomes for patients with head and neck cancers and non-small-cell lung cancer (NSCLC) has been identified.

The biomarker could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.

Scientists from the University of Pittsburgh (PA, USA) examined tumor samples from 187 patients with non-small-cell lung cancer and 60 patients with head and neck squamous cell carcinomas (HNSCC). The median follow-up for overall survival (OS) and disease-free survival (DFS) for NSCLC patients was 69.0 months and 35.9 months, respectively. The median follow-up for HNSCC patients was 41 months.

The team used antibody-based immunological techniques, cell cultures, immunoprecipitation, immunohistochemistry and in situ quantification. For tumor analysis, tissue microarrays of formalin-fixed and paraffin-embedded tumors and control tissues were used. Each tumor was represented by three distinct cores for NSCLC and two for HNSCC. The nuclear signal intensity was quantified by automated quantitative analysis for NSCLC and Aperio software for HNSCC (Aperio Technologies, Vista, CA, USA).

The investigators found that the expression of a protein called choline phosphate cytidylyltransferase-α CCT-α or CCTα, which acts as an “antigen” that prompts the immune system to produce antibodies against it. CCTα was associated with longer survival rates, including for patients with NSCLC who were treated with surgery alone, without the use of platinum-based chemotherapy drugs and associated toxic side effects.

Laura J. Niedernhofer, MD, PhD, an associate professor and a senior author of the study said, “Based on what we found, a high CCTα expression appears to be indicative of survival, making CCTα a promising biomarker. Our findings suggest that CCTα may, in fact, be more important in determining outcomes in patients with both types of cancer than the already established excision repair cross-complementation group 1 (ERCC1) protein.”

Related Links:

University of Pittsburgh
Aperio Technologies


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
Capillary Blood Collection Tube
IMPROMINI M3
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more